Source:http://linkedlifedata.com/resource/pubmed/id/17425621
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2007-4-25
|
pubmed:abstractText |
Adoptive immunotherapy using autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (auto-CTL) can regress posttransplant lymphoproliferative disorders (PTLD). Widespread applicability of auto-CTL remains constrained. Generation is time-consuming, and auto-CTL cannot be established in patients treated with the B-cell depleting antibody rituximab. By contrast, pregenerated allogeneic CTL (allo-CTL) offers immediate accessibility. Allo-CTL has previously shown efficacy in "early" polyclonal- PTLD. We treated three patients with aggressive, advanced monoclonal-PTLD following solid-organ transplantation. All were refractory to at least three prior therapies. Despite HLA disparity, there was negligible toxicity, with early in vivo antiviral efficacy and reconstitution of EBV peptide-specific immunity. Two patients attained complete remission (CR). One remains in CR 17 months following therapy, coincident with persistence of donor-derived tumor targeted EBV-specific CTL; the other died of non-PTLD related pathology. In the third patient, autopsy demonstrated homing of allo-CTL at the tumor site. Larger prospective studies of EBV-specific allo-CTL in PTLD are warranted.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1600-6135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1293-9
|
pubmed:meshHeading |
pubmed-meshheading:17425621-Adolescent,
pubmed-meshheading:17425621-Antibodies, Monoclonal,
pubmed-meshheading:17425621-Antibodies, Viral,
pubmed-meshheading:17425621-Female,
pubmed-meshheading:17425621-Heart Transplantation,
pubmed-meshheading:17425621-Herpesvirus 4, Human,
pubmed-meshheading:17425621-Humans,
pubmed-meshheading:17425621-Immunotherapy, Adoptive,
pubmed-meshheading:17425621-Kidney Transplantation,
pubmed-meshheading:17425621-Lung Transplantation,
pubmed-meshheading:17425621-Lymphoproliferative Disorders,
pubmed-meshheading:17425621-Middle Aged,
pubmed-meshheading:17425621-Receptors, Lymphocyte Homing,
pubmed-meshheading:17425621-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:17425621-Viral Load
|
pubmed:year |
2007
|
pubmed:articleTitle |
Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.
|
pubmed:affiliation |
Clinical Immunhaematology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia. maherG@qimr.edu.au
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|